Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
gegleucel
- Development stage
- Phase 2
- Lead developer
- Ingenium Therapeutics
- Modality
- CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
Gegleucel is an allogeneic memory natural killer (NK) cell therapy developed by Ingenium Therapeutics for the treatment of acute myeloid leukemia (AML). The therapy utilizes "cytokine-induced memory-like" (CIML) NK cells, which are generated by pre-activating donor-derived NK cells with a specific combination of cytokines, typically IL-12, IL-15, and IL-18. This ex vivo activation endows the NK cells with enhanced effector functions, including increased proliferative capacity, superior production of interferon-gamma, and improved persistence in the host compared to conventional NK cells. Gegleucel is designed to mediate potent anti-leukemia cytotoxicity to eliminate residual disease and prevent relapse in patients with hematologic malignancies. It is currently being evaluated in Phase 2 clinical trials for AML.
- Brand names
- Gengluecel
- Other names
- Gegleucel (AML)Allogeneic memory NK cell therapy
02
Targets
NKG2DL (NKG2D ligand family)IL-15R (Interleukin 15 receptor alpha/interleukin 15 complex)IL21R (Interleukin-21 receptor)
Beyond the preview
Go deeper on gegleucel.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on gegleucel.